Cargando…
The HIV-1 late domain-2 S(40)A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility
BACKGROUND: The p6 region of the HIV-1 structural precursor polyprotein, Gag, contains two motifs, P(7)TAP(11) and L(35)YPLXSL(41), designated as late (L) domain-1 and -2, respectively. These motifs bind the ESCRT-I factor Tsg101 and the ESCRT adaptor Alix, respectively, and are critical for efficie...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011916/ https://www.ncbi.nlm.nih.gov/pubmed/27600154 http://dx.doi.org/10.1186/s12977-016-0298-1 |
_version_ | 1782451920307224576 |
---|---|
author | Watanabe, Susan M. Simon, Viviana Durham, Natasha D. Kemp, Brittney R. Machihara, Satoshi Kemal, Kimdar Sherefa Shi, Binshan Foley, Brian Li, Hongru Chen, Benjamin K. Weiser, Barbara Burger, Harold Anastos, Kathryn Chen, Chaoping Carter, Carol A. |
author_facet | Watanabe, Susan M. Simon, Viviana Durham, Natasha D. Kemp, Brittney R. Machihara, Satoshi Kemal, Kimdar Sherefa Shi, Binshan Foley, Brian Li, Hongru Chen, Benjamin K. Weiser, Barbara Burger, Harold Anastos, Kathryn Chen, Chaoping Carter, Carol A. |
author_sort | Watanabe, Susan M. |
collection | PubMed |
description | BACKGROUND: The p6 region of the HIV-1 structural precursor polyprotein, Gag, contains two motifs, P(7)TAP(11) and L(35)YPLXSL(41), designated as late (L) domain-1 and -2, respectively. These motifs bind the ESCRT-I factor Tsg101 and the ESCRT adaptor Alix, respectively, and are critical for efficient budding of virus particles from the plasma membrane. L domain-2 is thought to be functionally redundant to PTAP. To identify possible other functions of L domain-2, we examined this motif in dominant viruses that emerged in a group of 14 women who had detectable levels of HIV-1 in both plasma and genital tract despite a history of current or previous antiretroviral therapy. RESULTS: Remarkably, variants possessing mutations or rare polymorphisms in the highly conserved L domain-2 were identified in seven of these women. A mutation in a conserved residue (S40A) that does not reduce Gag interaction with Alix and therefore did not reduce budding efficiency was further investigated. This mutation causes a simultaneous change in the Pol reading frame but exhibits little deficiency in Gag processing and virion maturation. Whether introduced into the HIV-1 NL4-3 strain genome or a model protease (PR) precursor, S40A reduced production of mature PR. This same mutation also led to high level detection of two extended forms of PR that were fairly stable compared to the WT in the presence of IDV at various concentrations; one of the extended forms was effective in trans processing even at micromolar IDV. CONCLUSIONS: Our results indicate that L domain-2, considered redundant in vitro, can undergo mutations in vivo that significantly alter PR function. These may contribute fitness benefits in both the absence and presence of PR inhibitor. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12977-016-0298-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5011916 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-50119162016-09-07 The HIV-1 late domain-2 S(40)A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility Watanabe, Susan M. Simon, Viviana Durham, Natasha D. Kemp, Brittney R. Machihara, Satoshi Kemal, Kimdar Sherefa Shi, Binshan Foley, Brian Li, Hongru Chen, Benjamin K. Weiser, Barbara Burger, Harold Anastos, Kathryn Chen, Chaoping Carter, Carol A. Retrovirology Research BACKGROUND: The p6 region of the HIV-1 structural precursor polyprotein, Gag, contains two motifs, P(7)TAP(11) and L(35)YPLXSL(41), designated as late (L) domain-1 and -2, respectively. These motifs bind the ESCRT-I factor Tsg101 and the ESCRT adaptor Alix, respectively, and are critical for efficient budding of virus particles from the plasma membrane. L domain-2 is thought to be functionally redundant to PTAP. To identify possible other functions of L domain-2, we examined this motif in dominant viruses that emerged in a group of 14 women who had detectable levels of HIV-1 in both plasma and genital tract despite a history of current or previous antiretroviral therapy. RESULTS: Remarkably, variants possessing mutations or rare polymorphisms in the highly conserved L domain-2 were identified in seven of these women. A mutation in a conserved residue (S40A) that does not reduce Gag interaction with Alix and therefore did not reduce budding efficiency was further investigated. This mutation causes a simultaneous change in the Pol reading frame but exhibits little deficiency in Gag processing and virion maturation. Whether introduced into the HIV-1 NL4-3 strain genome or a model protease (PR) precursor, S40A reduced production of mature PR. This same mutation also led to high level detection of two extended forms of PR that were fairly stable compared to the WT in the presence of IDV at various concentrations; one of the extended forms was effective in trans processing even at micromolar IDV. CONCLUSIONS: Our results indicate that L domain-2, considered redundant in vitro, can undergo mutations in vivo that significantly alter PR function. These may contribute fitness benefits in both the absence and presence of PR inhibitor. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12977-016-0298-1) contains supplementary material, which is available to authorized users. BioMed Central 2016-09-06 /pmc/articles/PMC5011916/ /pubmed/27600154 http://dx.doi.org/10.1186/s12977-016-0298-1 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Watanabe, Susan M. Simon, Viviana Durham, Natasha D. Kemp, Brittney R. Machihara, Satoshi Kemal, Kimdar Sherefa Shi, Binshan Foley, Brian Li, Hongru Chen, Benjamin K. Weiser, Barbara Burger, Harold Anastos, Kathryn Chen, Chaoping Carter, Carol A. The HIV-1 late domain-2 S(40)A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility |
title | The HIV-1 late domain-2 S(40)A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility |
title_full | The HIV-1 late domain-2 S(40)A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility |
title_fullStr | The HIV-1 late domain-2 S(40)A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility |
title_full_unstemmed | The HIV-1 late domain-2 S(40)A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility |
title_short | The HIV-1 late domain-2 S(40)A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility |
title_sort | hiv-1 late domain-2 s(40)a polymorphism in antiretroviral (or art)-exposed individuals influences protease inhibitor susceptibility |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011916/ https://www.ncbi.nlm.nih.gov/pubmed/27600154 http://dx.doi.org/10.1186/s12977-016-0298-1 |
work_keys_str_mv | AT watanabesusanm thehiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT simonviviana thehiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT durhamnatashad thehiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT kempbrittneyr thehiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT machiharasatoshi thehiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT kemalkimdarsherefa thehiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT shibinshan thehiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT foleybrian thehiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT lihongru thehiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT chenbenjamink thehiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT weiserbarbara thehiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT burgerharold thehiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT anastoskathryn thehiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT chenchaoping thehiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT cartercarola thehiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT watanabesusanm hiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT simonviviana hiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT durhamnatashad hiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT kempbrittneyr hiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT machiharasatoshi hiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT kemalkimdarsherefa hiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT shibinshan hiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT foleybrian hiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT lihongru hiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT chenbenjamink hiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT weiserbarbara hiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT burgerharold hiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT anastoskathryn hiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT chenchaoping hiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility AT cartercarola hiv1latedomain2s40apolymorphisminantiretroviralorartexposedindividualsinfluencesproteaseinhibitorsusceptibility |